文献速递血栓与止血

在血友病A或B患者中基于抗凝血酶的fitusiran剂量方案的安全性和有效性:ATLAS-OLE研究

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study.
PubMed 文献 · Blood · 2025-01-01

ATLAS-OLE是一项3期开放标签扩展研究,评估基于抗凝血酶(AT)的剂量方案(AT-DR)在≥12岁重型血友病A/B男性患者中的安全性和有效性。AT-DR将AT活性目标定为15%至35%,起始剂量为50 mg每2个月一次,个体化调整至20 mg每2个月一次或20/50/80 mg每月一次。中期分析时213例患者入组AT-DR,中位年化出血率为3.7,整合安全性分析显示AT-DR耐受良好,疗效优于按需凝血因子浓缩物和旁路制剂。

要点

  • AT-DR将AT活性目标设为15%至35%,起始剂量50 mg每2个月一次。
  • ATLAS-OLE中213例患者入组AT-DR,78%使用每2个月一次方案。
  • 中位年化出血率为3.7(四分位距0.0-7.5),每年最少6次注射可维持出血保护。

核心结论

  • Fitusiran AT-DR耐受良好,每年最少6次注射即可维持出血保护。

研究设计与样本

  • 3期开放标签扩展研究(ATLAS-OLE),纳入≥12岁重型血友病A/B男性患者,伴或不伴抑制物,评估AT-DR的安全性和有效性。
  • AT-DR起始剂量为50 mg每2个月一次,个体化调整至20 mg每2个月一次,或20/50/80 mg每月一次,目标AT活性15%至35%。
  • 整合安全性分析纳入接受AT-DR的286例患者,整合疗效分析将ATLAS-OLE中AT-DR的疗效与3期母研究对照组比较。
  • 试验注册号为NCT03754790。

主要发现

  • 中期数据截止时,213例患者入组AT-DR,其中78%使用每2个月一次方案。
  • ATLAS-OLE中AT-DR的中位年化出血率为3.7(四分位距0.0-7.5)。
  • 整合疗效分析显示AT-DR较按需凝血因子浓缩物(CFC)的平均年化出血率降低71%(P < .0001)。
  • AT-DR较按需旁路制剂(BPA)的平均年化出血率降低73%(P = .0006),较BPA预防的平均年化出血率降低70%。
  • AT-DR的年化出血率与CFC预防相当。

关键数值与推荐

  • AT-DR目标AT活性水平为15%至35%。
  • AT-DR起始剂量为50 mg每2个月一次,可个体化调整至20 mg每2个月一次,或20/50/80 mg每月一次。
  • AT-DR较按需CFC的平均年化出血率降低71%(P < .0001)。
  • AT-DR较按需BPA的平均年化出血率降低73%(P = .0006),较BPA预防降低70%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people with hemophilia. This phase 3 open-label extension study (ATLAS-OLE) evaluated safety and efficacy of an AT-based dose regimen (AT-DR) in males aged ≥12 years with severe hemophilia A/B, with/without inhibitors. The original dose regimen (ODR) of 80 mg monthly was optimized to AT-DR targeting AT activity levels 15% to 35% to mitigate thrombotic risk (starting dose of 50 mg once every 2 months, individually adjusted to 20 mg once every 2 months, or 20/50/80 mg monthly as needed). Primary and secondary end points were safety and efficacy, respectively. Integrated safety analyses assessed safety of AT-DR and ODR across all fitusiran studies and integrated efficacy analyses compared efficacy of AT-DR in ATLAS-OLE with phase 3 parent study control groups. At interim data cutoff, 213 participants were enrolled on AT-DR (78% on regimens of once every 2 months). Integrated safety analyses of participants receiving AT-DR (n = 286) demonstrated that AT-DR was well tolerated. In ATLAS-OLE, median observed annualized bleeding rate (ABR) with AT-DR was 3.7 (interquartile range, 0.0-7.5). Integrated efficacy analyses demonstrated superiority of AT-DR over on-demand clotting factor concentrates (CFCs; 71% mean ABR reduction; P < .0001), and on-demand bypassing agents (BPAs; 73% mean ABR reduction; P = .0006); improvement over BPA prophylaxis (70% mean ABR reduction); and ABR comparable with that observed with CFC prophylaxis. Fitusiran AT-DR was well tolerated and maintained bleed protection with as few as 6 injections per year. This trial was registered at www.ClinicalTrials.gov as #NCT03754790.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Young G, Kavakli K, Klamroth R, et al. Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study. Blood. 2025. PMID: 40053895. doi:10.1182/blood.2024027008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。